

School of Health And Related Research.



Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer Paul Tappenden, Alan Brennan, Jim Chilcott, Hazel Squires

Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, UK

INTRODUCTION

Conventional economic evaluation typically involves piecewise comparisons of competing technologies at a single isolated point in a broader care pathway. This study assesses the value of simulating whole disease and treatment pathways to provide a common economic basis for informing resource allocation decisions across an entire disease service. This "Whole Disease Modelling" approach was applied to the evaluation of technologies for the detection, diagnosis, treatment and follow-up of colorectal cancer with the intention of informing NICE's colorectal cancer clinical guideline¹ (see Box 1).

Box 1 Topics included in the scope of the NICE colorectal cancer clinical guideline

Topic A					
-	Effective diagnostic modalities in establishing a diagnosis of colorectal cancer in patients referred with suspicious symptoms.				
Topic B	Tumour staging for defining treatment in patients with colorectal cancer.				
Topic C	Curative treatment for patients with stage I or polyp cancer.				
Topic D	Treatment for patients presenting as emergencies with the symptoms of colorectal cancer.				
-	The sequence of local and systemic treatments in patients presenting with locally-advanced colorectal cancer.				
-	The sequence of local and systemic treatments in patients presenting with synchronous metastatic disease.				
•	Effectiveness of pre-operative a) short course radiotherapy and b) chemo-radiotherapy in treating patients with rectal cancer.				
-	For patients with stage II and III rectal cancer, the indications for adjuvant chemotherapy after surgery.				
-	For patients with high-risk stage II colon cancer, the indications for adjuvant chemotherapy after surgery.				
-	The sequence of ablation, surgery, regional therapy and systemic therapy, to achieve cure or long-term survival in patients with apparently incurable metastatic disease.				
	Clinical indications for performing liver metastasectomy in patients with colorectal cancer metastasised to the liver.				
•	Clinical indications for performing extrahepatic metastasectomy in patients with colorectal cancer.				
Topic M	Chemotherapy for patients with advanced and metastatic disease				
Topic N	Methods and frequencies of follow-up after potentially curative treatment for colorectal cancer.				
Topic O	Colorectal-specific support for patients diagnosed with colorectal cancer.				

RESULTS

The NICE guideline included fifteen individual economic evaluation topics. Under usual processes, conventional piecewise economic modelling would have been used to evaluate between one and three guideline topics. In contrast, the Whole Disease Model provided a consistent platform for the economic evaluation of eleven of the fifteen guideline topics, ranging from alternative diagnostic technologies through to cytotoxic treatments for metastatic disease. The constrained optimisation analysis identified a configuration of colorectal services which was expected to maximise QALY gains without exceeding current expenditure levels.


Торіс	Option	Cost	QALY	Inc. cost	Inc. QALY	ICER (QALY)
Baseline service		£105,486,388	14,636,144	-	-	-
٨	CT colonography	£102,244,329	14,636,316	£6,515,000	2488.98	£2,618
Α	FSIG→BE	£104,333,696	14,636,149	-	-	Dominated
	Baseline (COL)	£105,486,388	14,636,144	-	-	Dominated
	FSIG→COL	£95,729,329	14,633,827	-	-	-
	TEMS	£101,186,651	14,636,392	-£4,299,737	248.62	Dominating
C	Radical resection	£105,486,388	14,636,144	-	-	-
D ₁	Baseline	£105,486,388	14,636,144	£311,207	144.72	£2,150
	No CT scan	£105,175,181	14,635,999	-	-	-
	Baseline	£105,486,388	14,636,144	£311,207	144.72	£2,150
$\boldsymbol{\nu}_2$	No stenting	£105,175,181	14,635,999	-	-	-
_	All pre-op CRT	£106,231,677	14,636,458	£1,594,462	66.74	£23,891
E	All pre-op RT	£104,637,215	14,636,391	-	-	-
	Baseline	£105,486,388	14,636,144	-	-	Dominated
	No pre-op adjuvant tx	£106,168,990	14,636,050	-	-	Dominated
F	Simultaneous resection	£105,395,195	14,636,144	-£91,193	0.00	Dominating
	Baseline (staged)	£105,486,388	14,636,144	-	-	-
G	All pre-op CRT	£106,231,677	14,636,458	£1,594,462	66.74	£23,891
	All pre-op RT	£104,637,215	14,636,391	-	-	-
	Baseline	£105,486,388	14,636,144	-	-	Dominated
Η	Adjuvant chemo	£104,732,227	14,636,197	-£754,161	53.87	Dominating
	Baseline	£105,486,388	14,636,144	-	-	•
	Baseline	£105,486,388	14,636,144	-£307,136	144.35	Dominating
	No adjuvant chemo	£105,793,524	14,635,999	-2307,130	-	-
J	Baseline	£105,486,388	14,636,144	£1,149,942	18.62	£61,746
	HAI	£104,336,446	14,636,125	£15,388,185	775.42	£19,845
	BSC only	£88,948,261	14,635,350	-	-	-
Μ	CAPOX→CAPIRI	£106,742,491	14,636,221	£1,955,623	12.19	£160,437
	FOLFOX→FOLFIRI	£110,673,827	14,636,221	-	-	Dominated
	CAPOX→CAP	£104,786,868	14,636,209	£7,249,769	246.14	£29,454
	FOLFOX→5-FU/FA	£108,673,497	14,636,209	-	-	Dominated
	Baseline (current mix)	£105,486,388	14,636,144	-	-	Dominated
	CAPIRI→CAPOX	£105,670,207	14,636,104	-	-	Dominated
	FOLFIRI→FOLFOX	£109,670,755	14,636,104	-	-	Dominated
	CAPIRI→CAP	£102,804,556	14,636,081	-	-	Ext dom.
	FOLFIRI→5-FU/FA	£106,596,878	14,636,081	-	-	Dominated
	CAP→IR	£97,537,099	14,635,963	-	-	-
	5-FU/FA→IR	£100,722,827	14,635,963	-	-	Dominated
Ν	Baseline	£105,486,388	14,636,144	£2,160,699	142.83	£15,128
	Relaxed follow-up	£103,325,689	14,636,001	-	-	-

Table 1 Piecewise cost-effectiveness results estimated using the Whole Disease Model (300,000 simulated patients)


METHODS

A patient-level simulation model² was developed using SIMUL8 software (see Figure 1). The model simulates disease and treatment pathways from preclinical disease through to detection, diagnosis, adjuvant treatment, follow-up, treatments for metastases and supportive care. The model was populated using randomised controlled trials, observational studies, audit data, health utility studies, costing sources and expert opinion. Unobservable natural history parameters were calibrated against published data (incidence, stage at diagnosis, probability obstruction and adenomas prevalence) using Bayesian MCMC methods. Economic analysis was undertaken using (1) standard cost-utility decision rules within each guideline topic, and (2) constrained optimisation across all modelled topics.

Figure 1 The colorectal cancer Whole Disease Model







CONTACT

Paul Tappenden, Senior Research Fellow, Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, UK Email: p.tappenden@sheffield.ac.uk Tel: +44 (0) 114 222 0855 Fax: +44 (0) 114 272 4095 Web: www.shef.ac.uk/heds

FUNDING ACKNOWLEDGEMENT

This work was funded by the NIHR (project reference RDA/PAS03/2007/076). The views expressed here reflect those of the authors and do not necessarily reflect those of the NIHR. None of the authors have any conflicts of interest.

CONCLUSION

This study demonstrates that Whole Disease Modelling is feasible and can allow for the economic analysis of virtually any intervention across a disease service within a consistent conceptual and mathematical infrastructure. The approach may be especially valuable in instances whereby a substantial proportion of a disease service has not previously been subjected to formal economic evaluation.

REFERENCES

- (1) National Institute for Health and Clinical Excellence. The diagnosis and management of colorectal cancer: Clinical guideline (draft for consultation). Available from <u>http://www.nice.org.uk/nicemedia/live/11840/56067/56067.pdf</u> [date accessed 13/10/2011]
- (2) Tappenden P A methodological framework for developing Whole Disease Models: An application in colorectal cancer. PhD thesis. University of Sheffield. 2011